For the Inventor, By the Inventor

Enter assignee name

Porton Down, United Kingdom

Kalvista Pharmaceuticals Limited

USPTO Granted Patents = 23

CIPO Patents = 5

EPO Patents = 17

Trademarks = 4

Forward Citations = 98

Loading Chart...

Loading Chart...

38 inventors (with patents filed for the assignee):

Hannah Joy Edwards (16 out of 17 patents)

David Michael Evans (15 out of 25 patents)

Rebecca Louise Davie (13 out of 14 patents)

4. Simon Teanby Hodgson (9 out of 9 patents)

5. David Malcolm Crowe (4 out of 8 patents)

6. David Philip Rooker (4 out of 5 patents)

7. Andrew Richard Novak (3 out of 19 patents)

8. Gary Paul Cook (3 out of 12 patents)

9. Haydn Beaton (3 out of 3 patents)

10. Richard Simon Todd (2 out of 2 patents)

11. Theodore Patrick Laslo (2 out of 2 patents)

12. Premji Meghani (2 out of 40 patents)

13. Stephen John Pethen (2 out of 3 patents)

14. Alun John Smith (2 out of 5 patents)

15. Michael John Stocks (2 out of 2 patents)

23 patents: Sort by Forward Citations

1. 11739068 - Polymorphs of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereof (2023-08-29),

2. 11613527 - Enzyme inhibitors (2023-03-28),

3. 11584735 - Solid forms of a plasma kallikrein inhibitor and salts thereof (2023-02-21),

4. 11242333 - Inhibitors of plasma kallikrein (2022-02-08),

5. 11234939 - Dosage forms comprising a plasma kallikrein inhibitor (2022-02-01),

6. 11230537 - Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[2-oxopyridin-1-yl)methyl]phenyl} methyl)pyrazole-4-carboxamide as iallikrein inhibitors (2022-01-25),

7. 11198691 - N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors (2021-12-14),

8. 11180484 - Pyrazole derivatives as plasma kallikrein inhibitors (2021-11-23),

9. 11084809 - N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors (2021-08-10),

10. 11001578 - N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors (2021-05-11),

11. 10781181 - N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors (2020-09-22),

12. 10752607 - Polymorphs of N-[(6-cyano-2-fluoro)-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide as kallikrein inhibitors (2020-08-25),

13. 10611758 - N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors (2020-04-07),

14. 10478409 - Pharmaceutical compositions (2019-11-19),

15. 10364238 - N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors (2019-07-30),

KalVista Pharmaceuticals is a pharmaceutical company that specializes in the discovery, development, and commercialization of novel small molecule protease inhibitors for a range of diseases. With a core focus on plasma kallikrein inhibitors, KalVista aims to deliver innovative therapies for hereditary angioedema, diabetic macular edema, and other diseases.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

23 Patents

#1 in Porton Down

#765 in United Kingdom

#26,841 in the World

Porton Down, United Kingdom

Kalvista Pharmaceuticals Limited

Forward Citations = 98

38 inventors:

Hannah Joy Edwards (16 out of 17 patents)

David Michael Evans (15 out of 25 patents)

Rebecca Louise Davie (13 out of 14 patents)

4. Simon Teanby Hodgson (9 out of 9 patents)

5. David Malcolm Crowe (4 out of 8 patents)

Please report any incorrect information to support@idiyas.com

Loading…